Flying Brands Limited ECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IB (8040U)
17 7월 2018 - 3:00PM
UK Regulatory
TIDMFBDU
RNS Number : 8040U
Flying Brands Limited
17 July 2018
Flying Brands Limited
("Flying Brands" or the "Company")
ECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IMAGING
BIOMETRICS SOFTWARE
IB Rad Tech will be used to assess brain tumour treatment
response in multi-center trial
Imaging Biometrics(R), LLC ("IB"), a wholly-owned subsidiary of
Flying Brands Limited (LON:FBDU), and the American College of
Radiology Imaging Network ("ACRIN") have united efforts in a
multi-center Phase II trial sponsored by the Eastern Cooperative
Oncology Group (ECOG)-ACRIN Cancer Research Group. The study will
use IB Rad Tech(TM) to post-process datasets acquired from over 20
US sites to determine how well dynamic susceptibility contrast
magnetic resonance imaging (DSC-MRI) works in measuring relative
cerebral blood volume (rCBV) for early response to bevacizumab in
patients with recurrent glioblastoma, and to ultimately correlate
changes in rCBV to overall survival (OS) and progression free
survival (PFS).
Patients enrolled in the study will undergo a DSC-MRI exam right
before beginning treatment with bevacizumab (Genentech, San
Francisco). After the baseline exam, follow-up DSC-MRI exams will
be scheduled prior to the second dose administration of
bevacizumab, typically 2-3 weeks after the initial dose. In total,
165 patients are estimated to participate in the study.
IB Rad Tech, a customizable software interface, acts as a
"workflow wizard" to guide users through a series of automated
processing steps. The specific workflow used in this study will
leverage IB's FDA cleared software modules IB Neuro and IB Delta
Suite to easily determine the tumor region of interest (ROI) and
compute DSC-MRI-based normalized and standardized rCBV maps.
Exclusive to IB, standardization is a machine-learned calibration
approach that translates relative MR values to a fixed and
consistent scale regardless of scanner vendor, field strength, or
patient. The ability to automatically generate quantitative rCBV
values consistently, independent of scanner or timepoint, makes it
ideal for longitudinal assessment of treatment response.
ACRIN Principal Investigator Jerrold L. Boxerman, MD, PhD,
Associate Professor of Diagnostic Imaging at The Warren Alpert
Medical School of Brown University and Fellow of the American
College of Radiology, said "This study will help determine if rCBV
can serve as an early response imaging biomarker to an
anti-angiogenic agent (bevacizumab) in patients with recurrent
brain cancer. If successful, rCBV will lead the way for the
incorporation of more advanced imaging biomarkers into clinical
trials, which should help to improve the development efforts for
new cancer treatments. IB Rad Tech's ability to quantify how
patients are responding to treatment will provide for a more robust
study and greatly simplifies the post-processing of the numerous
datasets that we will acquire."
Michael Schmainda, CEO of IB said "We are delighted IB Software
was chosen for this important multi-center trial. Our quantitative
analysis resolves many inconsistencies that have inhibited routine
and robust brain tumour assessment, and has the potential to cause
a paradigm shift in how tumours are managed and treated. Moreover,
IB Rad Tech streamlines the processing in a very consistent and
cost-effective manner.".
ABOUT ACRIN
ACRIN has established a dynamic clinical trials infrastructure and developed numerous protocols
since its creation in 1999. These trials have the potential for altering and expanding the
role of medical imaging and image-guided therapy in the diagnosis and treatment of cancer.
Investigators from over 100 academic and community-based medical facilities in the United
States and several international institutions participate in ACRIN trials. The study, ACRIN
EAF151 (ClinicalTrials.gov Identifier: NCT03115333), is a five-year, phase II trial to assess
how well DSC-MRI works in measuring rCBV for early response to bevacizumab in patients with
recurrent glioblastoma.
ABOUT Imaging Biometrics(TM), LLC
Imaging Biometrics, a subsidiary of Flying Brands Limited
(LON:FBDU), develops and provides visualization and analytical
solutions that enable clinicians to better diagnose and treat
diseases with greater confidence. Through close collaboration with
top researchers and clinicians, sophisticated advancements are
translated into platform-independent software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualization
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com.
Flying Brands Limited (Ticker:FBDU) is the parent company of
StoneChecker(R) and Imaging Biometrics(R) focused on advanced and
state of the art medical software and services.
(www.flyingbrands.co.uk).
The Directors of the Company accept responsibility for the
contents of this announcement.
For further information, please contact:
Flying Brands Limited
Qu Li/Trevor Brown/Vinod Kaushal
Tel: 020 7469 0930
Peterhouse Corporate Finance (Financial
Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
-Ends-
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
STRFMGMNVVMGRZM
(END) Dow Jones Newswires
July 17, 2018 02:00 ET (06:00 GMT)
Flying Brand (LSE:FBDU)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Flying Brand (LSE:FBDU)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024